MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes

Table 2

Survival analysis of miRSNPs in mTOR pathway in 146 patients with limited-disease small cell lung cancer.

Gene SNP	Model		5yOS	HR (95% CI)	Log-rank	HR (95% CI) (adjusted)	adjusted
VEGFA rs10434	DOM	GG (100)	39.0%	0.768 (0.449–1.314)	0.334	0.864 (0.498–1.497)	0.601	0.651
		GA + AA (46)	39.7%
DDIT4 rs1053639	DOM	AA (87)	34.0%	0.949 (0.577–1.560)	0.835	0.910 (0.553–1.498)	0.712	0.688
		AT + TT (59)	44.8%
MAPK1 rs1063311	DOM	CC (107)	36.6%	0.637 (0.338–1.199)	0.158	0.546 (0.288–1.037)	0.064	0.165
		CT + TT (36)	45.8%
PTEN rs11202607	ADD	CC (122)	37.2%	0.714 (0.325–1.570)	0.400	0.596 (0.267–1.331)	0.207	0.391
		CT (23)	55.1%
PIK3R1 rs12755	REC	CA + CC (134)	28.7%	0.508 (0.284–0.909)	0.107	0.225 (0.054–0.931)	0.040	0.129
		AA (11)	55.7%
MTOR rs2536	ADD	TT (117)	43.4%	1.838 (1.033–3.272)	0.036	1.948 (1.090–3.482)	0.024	0.103
		TC (25)	22.9%
VEGFA rs3025039	DOM	CC (89)	42.3%	1.025 (0.617–1.705)	0.923	1.083 (0.639–1.837)	0.767	0.704
		CT + TT (55)	35.1%
PIK3R1 rs3756668	REC	GA + GG (119)	35.5%	0.417 (0.190–0.916)	0.025	0.388 (0.176–0.856)	0.019	0.103
		AA (25)	47.7%
PTEN rs701848	DOM	TT (52)	30.2%	0.802 (0.472–1.363)	0.413	0.725 (0.420–1.252)	0.249	0.435
		TC + CC (92)	41.9%

Adjusted for age, gender, Karnofsky performance score (KPS), smoking history, and Charlson comorbidity index (CCI).
miRSNPs: miRNA-related single nucleotide polymorphisms; OS: overall survival; HR: hazard ratio; CI: confidence interval.
Reference sequences: VEGFA GenBank NG_008732; DDIT4 GenBank NM_019058; MAPK1 GenBank NG_023054; PTEN GenBank NG_007466; PIK3R1 GenBank NG_012849; MTOR GenBank NG_033239.